Novo-Nordisk is a healthcare company focuses on diabetes care. Co. is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two segments: diabetes and obesity care and biopharm. Co. has one diabetes product portfolios, including insulin, a portfolio of modern insulin and human insulin as well as a portfolio of GLP-1 receptor agonists administered both via subcutaneous injection and as a tablet. Co.'s first product to treat obesity is Saxenda®. Co.'s second obesity treatment product is Wegovy®. In addition, Co.'s marketed portfolio includes haemophilia and growth hormone therapies.